LIMK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL664321	0.63	4/20
SCHEMBL96971	0.52	4/20
SCHEMBL254992	0.51	4/20
SCHEMBL396740	0.50	4/20
SCHEMBL257636	0.57	3/20
SCHEMBL692541	0.46	3/20
SCHEMBL180813	0.42	3/20
SCHEMBL180683	0.40	3/20
SCHEMBL180428	0.40	3/20
SCHEMBL181174	0.39	3/20
Tae-684 (SCHEMBL282775)	1.00	2/20
Capivasertib (SCHEMBL390243)	1.00	2/20
Capivasertib (SCHEMBL390244)	1.00	2/20
Capivasertib (SCHEMBL391382)	1.00	2/20
Danusertib (SCHEMBL466509)	1.00	2/20
SCHEMBL386619	0.90	2/20
SCHEMBL386620	0.90	2/20
SCHEMBL390401	0.90	2/20
SCHEMBL391567	0.87	2/20
SCHEMBL393210	0.87	2/20

Clinical trials — most relevant to LIMK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
A Trial of Metformin in Individuals With Fragile X Syndrome	PHASE2/PHASE3	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Immune Cell Response to Stimuli	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle?	nan	UNKNOWN
CAMK2-related Synapthopathies Natural History Study	nan	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)	nan	COMPLETED
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders	nan	UNKNOWN
Epidemiological and Genetic Studies of Body Mass Index	nan	COMPLETED
Biomarkers in Patients With Rhabdomyosarcoma	nan	COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Characterizing the Role of Pain Sensitivity in Acute to Persistent Low Back Pain	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LIMK2 binder may also engage these)

Protein	Name	Similarity
O54785	—	1.000	O54785 →
P53666	—	1.000	P53666 →
P53670	—	1.000	P53670 →
Q32L23	—	1.000	Q32L23 →
P53669	—	0.995	P53669 →
P53668	—	0.992	P53668 →
O42565	—	0.990	O42565 →
P09560	—	0.988	P09560 →
Q8QFP8	—	0.988	Q8QFP8 →
LIMK1	LIM domain kinase 1	0.987	landscape →
Q5R5M7	—	0.986	Q5R5M7 →
A7E3S4	—	0.985	A7E3S4 →
PLK2	Serine/threonine-protein kinase PLK2	0.985	landscape →
Q28GW8	—	0.984	Q28GW8 →
P11345	—	0.984	P11345 →
Q5R4L1	—	0.984	Q5R4L1 →
Q99N57	—	0.983	Q99N57 →
RAF1	RAF proto-oncogene serine/threonine-protein kinase	0.983	landscape →
P05625	—	0.983	P05625 →
Q91821	—	0.982	Q91821 →
P34908	—	0.981	P34908 →
O35346	—	0.981	O35346 →
P62205	—	0.981	P62205 →
Q00944	—	0.981	Q00944 →
Q62073	—	0.981	Q62073 →
PTK2	Focal adhesion kinase 1	0.981	landscape →
P34152	—	0.981	P34152 →
A2VDU3	—	0.981	A2VDU3 →
MAP3K3	Mitogen-activated protein kinase kinase kinase 3	0.981	landscape →
MELK	Maternal embryonic leucine zipper kinase	0.980	landscape →